Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-8

Financial Analysis:

"Dr Jackie Fairley, CEO, Starpharma, commented:These very positive results for DEP® cabazitaxel in three common and hard-to-treat cancers demonstrate its therapeutic and commercial value"

The phase 2 results look great and certainly demonstrate therapeutic value. Imo, financial things such as deals, sales and cash are needed to demonstrate commercial value. How close is SPL to achieving commercial results?

"Starpharma is engaged in ongoing commercial/licensing discussions with potential partners for DEP® cabazitaxel, and these final results form part of these discussions."

Sounds like the results have already been factored into the discussions. And no deal yet? How long before a deal will be announced? How long before a phase 3 trial can be completed? How long before a phase 3 trial can begin? How long before any commercial news at all from the hobby pharm?


Technical Analysis:

Another 8 million shares dumped today so far, with several hours still left in the day. That's about 2% of the shares on issue. With at least three large holders reducing their holdings, there could still be a large overhang. If the SP is above $0.16 at the end of the day, and then continues to rise and stays above $0.16 over the next few days then on the technical chart this would represent a breakout. Otherwise, the SP will still be within its long-term downtrend band, albeit in the upper region of the band. Holders can guess for themselves whether this would be technically a buy or a sell.